Search

A recent report from the University of Iowa discusses the complex pharmacokinetics of a small-molecule inhibitor called BI 187004, which targets 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD1). The study found that BI 187004 exhibited nonlinear pharmacokinetics at low doses and linear pharmacokinetics at higher doses. The researchers constructed a target-mediated drug disposition model to explain the nonlinear behavior and provide insights into the binding-related parameters of BI 187004. This modeling work will be useful for determining appropriate dose regimens for future clinical trials of BI 187004. [Extracted from the article]